-
-
-
-
-
-
-
Flexion Therapeutics (FLXN): Zilretta Approved with Strong Label - Laidlaw
-
-
-
-
-
-
-
Flexion Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
Flexion to Present New Cost-Effectiveness Data on Zilrettaâ„¢ (FX006) at the International Society for Pharmacoeconomics and Outcomes Research 22nd International Meeting
-
-
-
-
-
-
-
Flexion Therapeutics (FLXN): PDUFA Date Remains the Key Focus - RBC
-
-
-
-
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

